ITGAM and non-small cell lung carcinoma: ILT3 is also expressed on MDSCs, and the ILT3high fraction of PMN-MDSCs (CD11b+CD14−HLA-DR−CD33+CD15+) correlates with a relatively poor outcome in stage IV NSCLC patients [20].